Rampurwala, Murtuza
Wisinski, Kari B.
Burkard, Mark E.
Ehsani, Sima
O’Regan, Ruth M.
Carmichael, Lakeesha
Kim, KyungMann
Kolesar, Jill
Tevaarwerk, Amye J.
Article History
Received: 29 September 2016
Accepted: 20 October 2016
First Online: 8 November 2016
Compliance with ethical standards
:
: Murtuza Rampurwala declares that he has no conflict of interest.Kari B Wisinski declares that she has no conflict of interest.Mark E Burkard declares that he has no conflict of interest.Sima Ehsani declares that she has no conflict of interest.Ruth M O’Regan declares that she has no conflict of interest.Lakeesha Carmichael declares that she has no conflict of interest.KyungMann Kim declares that he has no conflict of interest.Jill Kolesar declares that she has no conflict of interest.Amye J Tevaarwerk declares that she has no conflict of interest.
: This study was funded by Millennium Pharmaceuticals. This work was supported by the NCI Cancer Center Support Grant P30 CA014520 and NCI U01CA062491 Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis. AJT and MEB have received support from the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grants UL1TR000427and KL2TR000428, while MR has received support from T32 CA009614.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.